MacroGenics, Inc. MGNX
2.17 USD -0.03 (-1.36%)
Regular-session close
2.10 -0.07 -3.23%
Pre-market · Nov 17, 5:14 AM ET
1.93 Day range 2.24
1.32 52-week range 5.08
- YTD
- +34.78%
- 1 year
- +44.67%
News
benzinga.com Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III…
zacks.com MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates MacroGenics (MGNX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to earnings of $0.27 per share a year ago.benzinga.com Macrogenics Q3 EPS $(0.34) Misses $(0.12) Estimate, Sales $18.667M Miss $43.748M Estimate Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.12) by 183.33 percent. This is a 342.86 percent decrease over earnings of…
globenewswire.com MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…benzinga.com MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily…
